Core Insights - The newly established company Gestala, co-founded by former CEO of Brain Tiger Technology Peng Lei and Chen Tianqiao, aims to explore next-generation brain signal reading and analysis through ultrasound brain-machine interface technology [2][5]. Company Overview - Gestala has set up operations in Chengdu Tianfu International Bio-City and is located in the Shanghai Brain-Machine Interface Industrial Cluster [2][5]. - The company plans to develop its products in phases, with the first generation focusing on chronic pain management and expected to initiate registration processes with the National Medical Products Administration (NMPA) by the end of 2026 [2][5]. Technology and Innovation - The ultrasound technology used by Gestala can indirectly decode neural activity by capturing blood flow signals, covering 25% of the entire brain volume while reaching deep brain areas and enabling simultaneous monitoring of multiple brain regions [2][5]. - This technology addresses the long-standing challenge in brain science research of balancing whole-brain imaging and real-time response, which has been difficult with existing methods like fMRI and invasive electrodes [2][5]. Industry Context - Chen Tianqiao has invested $1 billion over the past decade to support global brain science research and has successfully incubated multiple brain-machine interface companies through his firm, Shengda [3][6]. - The ultrasound brain-machine interface sector has seen significant financing activity, with companies like Merge Labs planning to raise $250 million at an $850 million valuation, and Nudge securing $100 million in Series A funding [3][6].

Core Viewpoint - The establishment of Gestalt Technology Co., Ltd. marks a significant advancement in non-invasive ultrasound brain-computer interface (BCI) technology, offering a new pathway in the BCI field [1][2]. Group 1: Technology Overview - Gestalt Technology specializes in ultrasound and phased array technology, differentiating itself from traditional invasive BCI methods [1]. - The non-invasive ultrasound BCI can modulate brain functions without the need for surgical procedures, unlike traditional invasive techniques that require drilling into the skull [1]. - The technology allows for high spatiotemporal resolution monitoring of brain signals, making it a promising direction for full-brain read/write capabilities [1]. Group 2: Product Development and Clinical Applications - The company plans to develop multiple generations of products, starting with a bench-top device, followed by a wearable device, and ultimately a semi-implantable device [2]. - The first product focuses on chronic pain management, currently undergoing clinical trials, with plans to initiate the registration process with the National Medical Products Administration by the end of the year [2]. - Clinical data shows significant potential, with pain intensity in chronic pain management reduced significantly and sustained for a week, and improvements in mood and depression scores within 24 hours for depression interventions [2]. Group 3: Collaborative Efforts and Industry Support - Gestalt Technology has established partnerships with several prestigious hospitals, including Fudan University Huashan Hospital and Peking Union Medical College Hospital, to enhance "industry-university-research-medical" collaboration [2]. - The collaboration aims to accelerate the clinical translation of ultrasound BCI technology, facilitating faster patient service [2]. - Sichuan Province has launched a special policy to promote the BCI industry, aiming to create a leading innovation development hub for BCI and human-computer interaction by 2030 [2][3]. Group 4: Ecosystem Development - The establishment of Gestalt Technology contributes to the formation of a more complete BCI ecosystem in Chengdu, leveraging the region's comprehensive resources in research, clinical practice, and medical innovation [3]. - The presence of top-tier clinical and research capabilities, exemplified by Sichuan University Huaxi Hospital, provides essential support for the innovation of medical devices like BCI [3].

Core Viewpoint - The establishment of Gestala, the first company in China focusing on ultrasound brain-machine interface technology, marks a significant advancement in the brain-machine interface sector in Chengdu, China [1][2]. Group 1: Company Overview - Gestala was founded on January 1, 2023, by Peng Lei and Chen Tianqiao, aiming to develop ultrasound brain-machine interface technology [1]. - The company is located in Chengdu, which is a key area for cutting-edge technology industries, particularly in brain-machine interfaces [1][2]. Group 2: Technology and Innovation - The ultrasound brain-machine interface is positioned as a promising technology for achieving "whole-brain read-write" capabilities, addressing various central nervous system disorders [2]. - Compared to traditional methods, ultrasound technology offers unique advantages in both "writing" and "reading" brain signals, with clinical studies showing significant effects on conditions like chronic pain and depression [2][3]. Group 3: Market Position and Future Plans - Since 2025, ultrasound brain-machine interfaces have become a global investment hotspot, with companies like Merge Labs achieving valuations of $850 million [3]. - Gestala plans to develop multiple product generations, starting with a bench-top device and moving to a wearable device, with the first product targeting chronic pain management expected to begin the NMPA registration process this year [3][4]. - The company aims to enhance collaboration across academia, industry, and healthcare to accelerate the clinical application of its technologies [3][4]. Group 4: Industry Context in Chengdu - Chengdu is rapidly advancing in the commercialization of brain-machine interface technologies, supported by local policies and academic resources [5]. - The city has become a hub for various technological paths in brain-machine interfaces, including invasive, non-invasive, and ultrasound methods, contributing to a more complete ecosystem in this field [5].